MN-ECOLAB
Ecolab Inc., a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life, today announced the successful sourcing of enough clean electricity to power 100% of its European operations, thanks to the completion of a windfarm project with the global renewable energy company, Low Carbon.
In 2022, Ecolab and Low Carbon entered into an agreement to develop the Mörknässkogen windfarm, located on the west coast of Finland near the city of Vaasa. Now, the windfarm has reached full commercial operation, and its 30MW capacity will generate approximately 100GWh of electricity annually. That’s enough to power 30,000 homes and avoid 20,000 tonnes of CO2e per year.
By sourcing the power produced by the windfarm, Ecolab will cover 100% of the electricity used across all its European sites, including 15 major offices, 26 manufacturing facilities and seven RD&E centers. This achievement elevates the company’s global renewable electricity sourcing level to 80%, marking a significant stride in Ecolab’s journey to achieving 100% renewable electricity globally by 2030, a key component of Ecolab’s 2030 Impact Goals.
"We believe that truly sustainable companies deliver on both their financial and environmental goals,” said Christophe Beck, Chairman and CEO, Ecolab. “By achieving this milestone in Europe, we'll be sourcing the renewable energy needed to power our operations and as we electrify our vehicle fleet. These efforts support our continued growth and ability to serve customers, all while moving us closer to our 2030 Impact Goals and a 100% positive future."
“We are delighted to see Low Carbon’s first Finnish wind project enter operations, which is a major milestone as we look to increase the amount of renewable energy capacity globally,” said John Isherwood, Managing Director at Low Carbon. “The 10-year PPA with our Ecolab partners underlines our shared vision for a world that is powered by renewables and will make a vital contribution to Finland’s supply of clean, secure energy.”
This latest renewable power milestone builds on Ecolab’s progress in North America, where the company reached 100% renewable electricity in 2020 as a result of its 2018 investment in the Mesquite Star windfarm in Texas and 2015 investment in a local community solar garden project in Minnesota.
As the electrical grids in major markets become greener, Ecolab’s virtual Power Purchase Agreements in North America and Europe account for the company’s transition to electric vehicles. Ecolab recently announced accelerated efforts to electrify its sales and service fleet in North America by 2030.
Ecolab’s Power Purchase Agreements and its other initiatives put the company on pace to achieve its renewable electricity targets by 2030. That’s well ahead of guidelines outlined by RE100, a global corporate initiative focused on achieving 100% renewable electricity by 2050, of which Ecolab is a member.
For more information on Ecolab’s 2030 Impact Goals, visit ecolab.com/corporate-responsibility/2030-impact-goals. For more information on Ecolab’s commitment to operating sustainably, visit ecolab.com/corporate-responsibility.
About Ecolab
A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on a century of innovation, Ecolab has annual sales of $15 billion, employs more than 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, life sciences, hospitality and industrial markets.
Follow us on LinkedIn @Ecolab, Twitter @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab.
About Low Carbon
Low Carbon creates large-scale renewable energy to fight climate change. We’re building a net-zero energy company that will protect the planet for future generations. This defining purpose drives us to deliver for our communities, investors, and the environment. We are a long-standing certified B-Corporation and recognized as a gold standard for our environmental impact.
We invest in, develop, and operate solar, wind, energy storage, and energy from waste projects across the UK, Europe, and North America. We’re contributing to the world’s move to 100% renewable energy by creating and operating 20GW of new capacity by 2030.
We have more than 8GW in new renewables in development right now across the globe.
Low Carbon is on a mission. Together, we will power tomorrow.
(ECL-C)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313546541/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
